Brise Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative analgesic treatments for acute and chronic pain. Led by CEO Dr. Guochun Li, the company focuses on migraine, neuropathic and musculoskeletal pain. Brise has advanced two molecules to the clinical stage in the US and China. It employs biology-based drug development platforms centered on the Trigeminovascular System (TVS) and the Dorsal Root Ganglion (DRG). The company recently completed Pre-A and Pre-A+ financings totaling approximately $20M. Proceeds will be used to advance its product pipeline in preclinical and clinical stages and to further refine and validate its TVS and DRG platforms. 熙源安健医药（上海）有限公司 is developing a global-leading pipeline of innovative analgesic drugs focused on pain targets with clear human genetic and pathophysiologic rationale. The company pursues the optimal therapeutic modalities and dosing routes and builds its pipeline via self-R&D, collaboration and M&A. It plans to use flexible clinical strategies to broaden drug accessibility and commercial value. Management is also seeking partners in medical devices, digital therapeutics and health management to create integrated, long-term pain-management solutions. The company aims to establish commercial channels first in China and then expand overseas. CEO Li Guochun has prior experience running pain-innovation projects at a large U.S. pharma, and the team emphasizes translating deeper clinical understanding of pain into new therapies.

Total raised

$36M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2024